ClinConnect ClinConnect Logo
Search / Trial NCT06547216

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Launched by AVIDITY BIOSCIENCES, INC. · Aug 7, 2024

Trial Information

Current as of April 30, 2025

Enrolling by invitation

Keywords

Fortitude Avidity Avidity Biosciences Aoc 1020 Fortitude Ole Fortitude Ole

ClinConnect Summary

This study will continue to evaluate the safety, tolerability, and efficacy of AOC 1020 in participants who were treated in the randomized, placebo-controlled, Phase 1/2 AOC 1020-CS1 clinical study.

Participants from AOC 1020-CS1 are eligible to enroll in AOC 1020-CS2 if they have satisfactorily completed AOC 1020-CS1. All participants who enroll in AOC 1020-CS2 will receive AOC 1020 regardless of whether they received AOC 1020 or placebo in AOC 1020-CS1. Dosing will occur every 6 to 7 weeks (twice quarterly).

The total duration of active treatment in AOC 1020-CS2 is approximately 22 mont...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Ability to provide written informed consent (signed and dated) and any authorizations required by local law and be willing and able to comply with all study requirements. When enrolling participants who are minors, it is necessary to also obtain consent from a legally designated representative and the participant will receive information in a way adapted to their age and mental maturity.
  • 2. Completion of AOC 1020-CS1 with the following as judged by the Investigator and Sponsor:
  • 1. No significant tolerability issues
  • 2. Satisfactory compliance with the AOC 1020-CS1 protocol requirements
  • Exclusion Criteria:
  • 1. Pregnancy, intent to become pregnant during the clinical study, or active breastfeeding.
  • 2. Unwilling or unable to continue to comply with contraceptive requirements for the length of AOC 1020-CS2.
  • 3. Any new conditions or worsening of existing condition(s) that in the opinion of the Investigator or Sponsor would make the participant unsuitable for the study or could interfere with participation or completion of the study. (Note: FSHD progression is not exclusionary, even if the participant no longer has the ability to walk 10 meters without a walker or two canes.)

About Avidity Biosciences, Inc.

Avidity Biosciences, Inc. is a pioneering biotechnology company focused on developing innovative therapeutics for the treatment of serious diseases. Leveraging its proprietary Avidity™ platform, the company specializes in advancing antibody-drug conjugates and other targeted therapies that enhance the delivery and efficacy of biologics. With a commitment to transforming patient outcomes, Avidity Biosciences aims to address unmet medical needs through cutting-edge research and development, fostering collaborations to drive forward the next generation of biopharmaceuticals.

Locations

Philadelphia, Pennsylvania, United States

Columbus, Ohio, United States

Durham, North Carolina, United States

Rochester, New York, United States

Seattle, Washington, United States

Palo Alto, California, United States

Gainesville, Florida, United States

Denver, Colorado, United States

Richmond, Virginia, United States

Los Angeles, California, United States

Dallas, Texas, United States

San Diego, California, United States

Ottawa, Ontario, Canada

Durham, North Carolina, United States

Sheffield, , United Kingdom

Atlanta, Georgia, United States

Kansas City, Kansas, United States

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Amy Halseth, Ph.D.

Study Director

Avidity Biosciences, Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported